These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23574794)

  • 21. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy.
    Antinori A; Cingolani A; Alba L; Ammassari A; Serraino D; Ciancio BC; Palmieri F; De Luca A; Larocca LM; Ruco L; Ippolito G; Cauda R
    AIDS; 2001 Aug; 15(12):1483-91. PubMed ID: 11504980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [HIV-related non-Hodgkin lymphoma in 45 patients; a retrospective analysis].
    Kersten MJ; Mertens MJ; Pals ST; Reiss P; van Oers MH
    Ned Tijdschr Geneeskd; 1993 Jul; 137(28):1396-400. PubMed ID: 8345893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical features and predictors of survival of AIDS-related non-Hodgkin's lymphoma in a population-based case series in Sydney, Australia.
    Robotin MC; Law MG; Milliken S; Goldstein D; Garsia RJ; Dolan GM; Kaldor JM; Grulich AE
    HIV Med; 2004 Sep; 5(5):377-84. PubMed ID: 15369514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome in patients with non-hodgkin lymphoma and with or without human immunodeficiency virus infection.
    Spina M; Carbone A; Vaccher E; Gloghini A; Talamini R; Cinelli R; Martellotta F; Tirelli U
    Clin Infect Dis; 2004 Jan; 38(1):142-4. PubMed ID: 14679461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients.
    Wyen C; Jensen B; Hentrich M; Siehl J; Sabranski M; Esser S; Gillor D; Müller M; Van Lunzen J; Wolf T; Bogner JR; Wasmuth JC; Christ H; Fätkenheuer G; Hoffmann C
    AIDS; 2012 Feb; 26(4):457-64. PubMed ID: 22112600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoplasms and infections as the main causes of death in patients in complete response to HIV-related non-Hodgkin lymphoma in the combination antiretroviral therapy era: a study out of a series of 146 patients.
    Navarro JT; Baptista MJ; Morgades M; Tural C; Millá F; Feliu E; Ribera JM
    Br J Haematol; 2013 Jul; 162(2):289-91. PubMed ID: 23617413
    [No Abstract]   [Full Text] [Related]  

  • 27. Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma.
    Montoto S; Wilson J; Shaw K; Heath M; Wilson A; McNamara C; Orkin C; Nelson M; Johnson M; Bower M; Cwynarski K
    AIDS; 2010 Mar; 24(6):851-6. PubMed ID: 20124971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
    Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
    J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
    Spina M; Simonelli C; Tirelli U
    J Clin Oncol; 2007 Feb; 25(6):e7. PubMed ID: 17308261
    [No Abstract]   [Full Text] [Related]  

  • 30. Disseminated plasmablastic lymphoma.
    Sharma R; Abdou S; Plymyer MR; Rohatgi C
    J Am Coll Surg; 2004 Oct; 199(4):654-5. PubMed ID: 15454154
    [No Abstract]   [Full Text] [Related]  

  • 31. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS.
    Boulanger E; Gérard L; Gabarre J; Molina JM; Rapp C; Abino JF; Cadranel J; Chevret S; Oksenhendler E
    J Clin Oncol; 2005 Jul; 23(19):4372-80. PubMed ID: 15994147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. International prognostic index is the best prognostic factor for survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP. A multivariate study of 46 patients.
    Navarro JT; Ribera JM; Oriol A; Vaquero M; Romeu J; Batlle M; Gómez J; Millá F; Feliu E
    Haematologica; 1998 Jun; 83(6):508-13. PubMed ID: 9676023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases.
    Castillo J; Pantanowitz L; Dezube BJ
    Am J Hematol; 2008 Oct; 83(10):804-9. PubMed ID: 18756521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy.
    Lim ST; Karim R; Tulpule A; Nathwani BN; Levine AM
    J Clin Oncol; 2005 Nov; 23(33):8477-82. PubMed ID: 16230675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.
    Cheung MC; Pantanowitz L; Dezube BJ
    Oncologist; 2005; 10(6):412-26. PubMed ID: 15967835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa.
    Mwanda WO; Orem J; Fu P; Banura C; Kakembo J; Onyango CA; Ness A; Reynolds S; Johnson JL; Subbiah V; Bako J; Wabinga H; Abdallah FK; Meyerson HJ; Whalen CC; Lederman MM; Black J; Ayers LW; Katongole-Mbidde E; Remick SC
    J Clin Oncol; 2009 Jul; 27(21):3480-8. PubMed ID: 19470940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AIDS-related lymphomas--potentially curable in the HAART era.
    Valencia ME
    AIDS Rev; 2006; 8(2):108-10. PubMed ID: 16848278
    [No Abstract]   [Full Text] [Related]  

  • 38. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy.
    Bower M; Gazzard B; Mandalia S; Newsom-Davis T; Thirlwell C; Dhillon T; Young AM; Powles T; Gaya A; Nelson M; Stebbing J
    Ann Intern Med; 2005 Aug; 143(4):265-73. PubMed ID: 16103470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial.
    Weiss R; Mitrou P; Arasteh K; Schuermann D; Hentrich M; Duehrsen U; Sudeck H; Schmidt-Wolf IG; Anagnostopoulos I; Huhn D
    Cancer; 2006 Apr; 106(7):1560-8. PubMed ID: 16502436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
    Boué F; Gabarre J; Gisselbrecht C; Reynes J; Cheret A; Bonnet F; Billaud E; Raphael M; Lancar R; Costagliola D
    J Clin Oncol; 2006 Sep; 24(25):4123-8. PubMed ID: 16896005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.